| abstract |
The present invention relates to a compound represented by the following general formula (1):n n n n n n n n n n Wheren n n A is R 1 q (R 3 R 60 N) m (Z) (NR 2 ) n ,n n n m and q are each 0 or 1 (where m is 0 when q is 1 and m is 1 when q is 0),n n n Z is C = O or SO 2 (where m is 1 when Z is C = O),n n n n is 1,n n n X is -NH-, -CH 2 -or -OCH 2- ,n n n Y is 2-imidazoline, 2-oxazoline, 2-thiazoline or 4-imidazole,n n n R 1 is H, lower alkyl or phenyl (wherein m is 1 when R 1 is H),n n n R 2 , R 3 and R 60 are each independently H, lower alkyl or phenyl,n n n R 4 , R 5 , R 6 and R 7 are each independently hydrogen, lower alkyl, -CF 3 , lower alkoxy, halogen, phenyl, lower alkenyl, hydroxy, lower alkylsulfonamido or lower cycloalkyl,n n n Optionally R 2 and R 7 may together form C 2 -C 3 alkylene or alkenylene in an unsubstituted or optionally substituted 5- or 6-membered ring, wherein the optional substituents of this ring are halo , Lower alkyl or -CN,n n n However, R 7 is hydroxy, or if lower alkyl sulfonamido Y is 2-1 when X imidazoline is not -NH-.n n n The present invention includes pharmaceutically acceptable salts of the compounds. In Formula 1, A may be, for example, (R 1 SO 2 NR 2- ), (R 3 R 60 NSO 2 NR 2- ), or (R 3 R 60 NCONR 2- ). The invention also relates to various disease states such as urinary incontinence, nasal congestion, penile stiffness, depression, anxiety, dementia, aging, concentration and cognitive deficits such as Alzheimer's disease and eating disorders (e.g. hypertrophy, bulimia and anorexia). The use of said compound as an α A / 1L -agent in the treatment of a composition and a composition containing the same. |